Raysun Intelligence Completes Over RMB 100 Million Series A Financing, Unveiling a New Paradigm for Digital Dental Manufacturing

VCBeat has learned that on October 24, Suzhou Laisai Intelligence Technology Co., Ltd. (hereinafter referred to as “RAYSHAPE”), a comprehensive provider of 3D printing solutions for dentistry, announced the completion of its Series A financing round, which exceeded RMB 100 million. The round was led by SHARE LINK VENTURE CAPITAL CO.,Ltd., with participation from several senior entrepreneurs in the dental industry. Index Capital served as the exclusive financial advisor. The proceeds will be primarily used to expand production capacity and broaden overseas markets.

The digitalization of healthcare in China has been elevated to the level of national strategy, with dental digitalization serving as a crucial component of this broader transformation. 3D printing technology is widely applied in various areas, including dental restoration, dental implants, and aligner fabrication, continuously expanding digital dentistry application scenarios and driving the transition from labor-intensive manufacturing to intelligent manufacturing. Currently, dental 3D printing solutions offer advantages such as customization, low material waste, and high precision, and are undergoing a critical shift from being an “optional” choice to a “mandatory” one. According to SmarTech data, the global market size for 3D-printed dentistry reached $3.5 billion in 2021 and is projected to reach $9 billion by 2028.

RAYSHAPE is a provider of integrated digital production solutions based on 3D printing. Led by a founding team with over ten years of experience in the 3D printing industry, featuring comprehensive expertise, profound technical accumulation, and mature operational philosophy, RAYSHAPE possesses complete independent R&D capabilities across optical, electrical, mechanical, software, algorithmic, and material aspects of stereolithography (SLA) 3D printing, including AI solution design and material research and development. The company delivers comprehensive, leading-edge integrated solutions for diverse industries and application scenarios, encompassing the development, manufacturing, and sales of 3D printing equipment, software, materials, and technical solutions.

RAYSHAPE leverages foundational industrial design, electronic and electrical products, digital dentistry, and science education and cultural creativity as key application entry points. It has launched multiple 3D printing devices across its Shape, P, and Edge series, along with supporting software, more than 20 high-performance photosensitive resin materials, and end-use products, providing comprehensive product solutions and implementation services for diverse application areas.

In terms of equipment, RAYSHAPE currently offers three mainstream models: Shape 1+Dental, Edge E2, and Edge Max. These models cater to diverse application scenarios such as chairside and dental laboratory settings, providing a tiered product selection with varying build volumes, printing speeds, and printing accuracies. With significant advantages including high reliability, high accuracy, cost-effectiveness, and user-friendliness, RAYSHAPE has rapidly captured the global dental 3D printing market.

Furthermore, RAYSHAPE has independently developed over 20 resin materials specifically tailored for distinct dental applications. Some of these products have already received approval from the NMPA and FDA, with concurrent applications submitted for Class III medical device registration certificates. Its newly developed 3D-printed customized denture bases are poised to become a next-generation solution for edentulous jaws. Looking ahead, RAYSHAPE will accelerate its strategic layout in removable partial dentures and permanent prosthetics, leading innovative transformations in the field of restorative and implant dentistry.

Leveraging its comprehensive product portfolio and competitive advantages, RAYSHAPE has established a presence across multiple dental sub-sectors, including leading dental laboratories, top-tier public hospitals, large dental chain clinics, major channel distributors, and leading brand manufacturers.

To date, RAYSHAPE has cumulatively shipped thousands of units, accumulating a substantial portfolio of benchmark client cases across multiple sectors. These include leading medical device manufacturers such as Huawei, Mindray, United Imaging, and Yuwell; over 1,000 dental laboratory facilities, including Kangtaijian, Jiahong, Dentech, and Dekaili; and hundreds of dental hospitals and clinics, such as West China Hospital of Stomatology at Sichuan University, Wuhan University School of Stomatology, Arrail Dental, and Happy Dental.

In overseas markets, RAYSHAPE has focused its efforts on key countries along the Belt and Road Initiative, continuously advancing its global expansion. The company has established subsidiaries in Europe and the United States, extending its reach to 60 countries across regions including Europe, North Africa, Asia-Pacific, North America, and Central and South America. It has formed partnerships with more than 120 overseas companies, such as Viet Dang, Novadent, and Unident, driving sustained growth in its international revenue.

Liu Zhen, Founder and CEO of RAYSHAPE, previously served as the R&D Director at a leading domestic 3D printing equipment manufacturer, where he was responsible for product line R&D and operational management. The team’s leaders in technology, materials, algorithms, and application services possess extensive professional experience in industries such as 3D printing, electromechanics, and photocurable materials, combining deep expertise in digital dentistry with global business capabilities. This rare team, characterized by comprehensive business capabilities and profound technical accumulation, has gained unanimous recognition from investment institutions.

SHARE LINK VENTURE CAPITAL, the lead investor in this funding round, stated: “SHARE LINK has consistently focused on innovative applications of 3D printing technology. The dental industry represents one of the most promising commercial scenarios for 3D printing, reshaping the landscape of dental laboratory services by delivering more comfortable patient experiences, more efficient diagnostic and treatment workflows, and cost-effective personalized denture customization. Aligning with the wave of digitalization in dentistry, 3D printing equipment and materials hold substantial market potential in the dental sector. We highly recognize RAYSHAPE’s exceptional product capabilities and efficient operational excellence. With rapid growth in the shipment volume of its equipment and materials, the company is well-positioned to remain a leader in this niche industry.”

Chen Ge, Senior Vice President of Index Capital, stated, “We have always paid close attention to innovative technologies in the consumer healthcare sector. As a paradigmatic application of new quality productive forces in medical scenarios, 3D printing is continuously reshaping the original productivity and production relations across various industrial chains. The dental industry, characterized by its high degree of customization, has become the niche segment within the medical industry where 3D printing achieves commercialization most rapidly. We highly appreciate RAYSHAPE’s product development philosophy, which delivers high-quality products that combine industrial-grade technology with consumer-level cost efficiency. Through technological innovation, RAYSHAPE brings superior product experiences to a broader range of industry users. We believe that RAYSHAPE will emerge as a global leader in 3D printing, spearheading the next wave of transformation in the dental industry.”